account$885 million for an 18.4% stake in Elan and acquired rights to advanced research into drugs for Alzheimer's disease, representing most of the value credited to the Elan Alzheimer's pipeline at the time. Mr. Martin, who steps down as CEO in a year from...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Elan Sells EDT Unit to Alkermes
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account